Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EPS (Basic): 2020-2025

Historic EPS (Basic) for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Sep 2025 value amounting to -$0.30.

  • Tarsus Pharmaceuticals' EPS (Basic) rose 50.82% to -$0.30 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.01, marking a year-over-year increase of 46.68%. This contributed to the annual value of -$3.07 for FY2024, which is 33.55% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its EPS (Basic) stood at -$0.30 for Q3 2025, which was up 37.50% from -$0.48 recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' EPS (Basic) peaked at $0.31 during Q2 2021, and registered a low of -$1.28 during Q3 2023.
  • Its 3-year average for EPS (Basic) is -$0.83, with a median of -$0.88 in 2024.
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 125.20% in 2021, then tumbled by 387.50% in 2023.
  • Quarterly analysis of 5 years shows Tarsus Pharmaceuticals' EPS (Basic) stood at -$0.72 in 2021, then soared by 31.94% to -$0.49 in 2022, then tumbled by 159.18% to -$1.27 in 2023, then soared by 53.54% to -$0.59 in 2024, then soared by 50.82% to -$0.30 in 2025.
  • Its EPS (Basic) stands at -$0.30 for Q3 2025, versus -$0.48 for Q2 2025 and -$0.64 for Q1 2025.